Claims
- 1. A method for treating patients having premalignant or precancerous lesions whle are leukoplakias or dysplasias to retard the progression of these lesions into carcinomas comprising administering to said patient a composition containing the compound 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(alpha-methylstyryl)naphthalene, said compound being administered in an amount effective to treat said lesions.
- 2. The method of claim 1 wherein said compound is 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[(E)-alpha-methylstyryl]naphthalene.
- 3. The method of claim 1 wherein said composition is administered orally.
- 4. The method of claim 3 wherein compound is administered at a daily amount dose of from 1 mg to 50 mg per kg body weight.
- 5. The method of claim 4 wherein said lesions are leukoplakias of the oral cavity.
- 6. The method of claim 4 wherein said lesions are precancerous epithelial lesions of the breast.
- 7. The method of claim 4 wherein said composition is administered at a daily dose of from 3 mg to 15 mg per kg body weight.
- 8. The method of claim 7 wherein said composition is administered in an oral unit dosage form containing 150 mg to 500 mg of the compound.
- 9. The method of claim 8 wherein said oral unit dosage form is a capsule or tablet.
- 10. A method for treating patients who have had a treated primary malignancy which is an epithelial carcinoma to inhibit the development of second primary malignancy or a recurrence of said treated primary malignancy comprising administering to said patients a composition containing the compound 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(alpha-methylstyryl)naphthalene, said compound being administered in an amount effective to inhibit the development of a second primary malignancy or recurrence of said treated primary malignancy.
- 11. The method of claim 10 wherein said compound is 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[(E)-alpha-methylstyryl]naphthalene.
- 12. The method of claim 10 wherein said composition is administered orally.
- 13. The method of claim 12 wherein said compound is administered at a daily dose of from 1 mg to 50 mg per kg body weight.
- 14. The method of claim 13 wherein said treated primary malignancy is an epithelial carcinoma of the breast, skin, colon, bladder, esophagus, stomach, larynx, lung or oral cavity.
- 15. The method of claim 14 wherein said treated primary malignancy is a carcinoma of the breast.
- 16. The method of claim 13 wherein said composition is administered at a daily dose of 3 mg to 15 mg per kg body weight.
- 17. The method of claim 16 wherein said composition is administered in an oral unit dosage form containing 150 mg to 500 mg of the compound.
- 18. The method of claim 17 wherein said oral unit dosage form is a capsule or tablet.
- 19. A method for treating tumors of epithelial origin in patients to retard the development of these tumors comprising administering to said patient a composition containing the compound 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(alpha-methylstyryl)naphthalene, said compound being administered in an amount effective to retard the development of said tumors.
- 20. The method of claim 19 wherein said compound is 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[(E)-alphamethylstyryl]naphthalene.
- 21. The methodof claim 19 wherein said composition is administered orally.
- 22. The method of claim 21 wherein said compound is administered at a daily dose of from 1 mg to 50 mg per kg body weight.
- 23. The method of claim 22 wherein said tumors are selected from the group consisting of epithelial tumors of the breast, skin, colon, bladder, esophagus, stomach, larynx, lung or oral cavity.
- 24. The method of claim 23 wherein said tumor is an epithelial carcinoma of the breast.
- 25. The method of claim 22 wherein said compound is administered at a daily dose of from 3 mg to 15 mg per kg body weight.
- 26. The method of claim 25 wherein said composition is administered in an oral unit dosage form containing 150 mg to 500 mg of the compound.
- 27. The method of claim 26 wherein said oral unit dosage form is a capsule or tablet.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2755/85 |
Jun 1985 |
CHX |
|
Parent Case Info
This is a continuation of application Ser. No. 874-932 filed 6/16/86, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4588750 |
Boris |
May 1986 |
|
Non-Patent Literature Citations (2)
Entry |
The Merck Manual, 1982, Merck & Co., Inc., Rahway, N.J., p. 2110. |
Loeliger et al., Eur. J. Med. Chem.,-Chemica Therapeutica 15, No. 1, pp. 9-15 (1980). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
874932 |
Jun 1986 |
|